健康中国筑牢幸福根基

Core Points - The Chinese government prioritizes public health and has established a comprehensive basic medical security system covering over 1.3 billion people, with life expectancy increasing from 35 years at the founding of New China to 79 years by 2024 [1] - The multi-tiered medical insurance system has been significantly improved, allowing for direct settlement of medical expenses across provinces, with an expected 238 million cross-province medical visits by the end of 2024 [2][3] - The pharmaceutical industry is experiencing a surge in innovation, with 48 new drugs approved in 2024 and a shift from "follow-up innovation" to "original breakthroughs" [5] Group 1: Medical Insurance and Coverage - By the end of 2024, approximately 1.327 billion people will be covered by basic medical insurance, maintaining a coverage rate of over 95% [3] - The cumulative financial relief for low-income rural populations during the 14th Five-Year Plan period exceeds 650 billion yuan [3] Group 2: Pharmaceutical Innovation - The first domestically developed long-acting interferon for hepatitis B has been launched, significantly reducing treatment costs and improving patient access [4] - The rapid development of the pharmaceutical industry is supported by government policies that facilitate faster access to innovative drugs [4] Group 3: Public Health and Disease Prevention - A robust infectious disease reporting system has been established, enhancing early detection and response capabilities for major chronic diseases [6][7] - The vaccination strategy has been adjusted to strengthen herd immunity, with a high vaccination rate of over 90% among eligible children [8]